Get the Daily Brief
Latest Biotech News
Novo Nordisk’s $550M Deal with Replicate for Self-Replicating RNA Drugs
Novo Nordisk has inked a research collaboration potentially worth $550 million with Replicate Bioscience to develop next-generation metabolic drugs using self-replicating RNA (srRNA) technology....
Advanced Multiomics Platform by Pleno Gains Early Access Adoption
Pleno, a San Diego-based company, has launched an early-access program for its Raptor multiomics biomarker detection platform, positioning for a full commercial debut by 2026 or 2027. The...
Breakthrough AI Model Achieves High Success in Protein Binder Design
Researchers at EPFL have unveiled BindCraft, an AI-powered pipeline capable of designing functional protein binders against diverse targets with remarkable 10–100% success rates without extensive...
Wugen Raises $115M to Advance Off-the-Shelf CAR-T Therapy
Wugen Inc., a cell therapy company based in St. Louis, has secured $115 million in funding led by Fidelity Management to advance its allogeneic, off-the-shelf CAR-T therapy for T-cell...
Temporomandibular Joint Osteoarthritis Modulated by Soluble Epoxide Hydrolase
A study published in the Journal of Translational Medicine reveals that targeting soluble epoxide hydrolase (sEH) can modulate M1 macrophage polarization and ease symptoms in temporomandibular...
Tempus Acquires Paige to Expand AI-Driven Digital Pathology Capacities
Tempus has acquired Paige, a digital pathology firm with one of the largest annotated pathology slide datasets globally, for $81.3 million in stock and assumed cloud contract commitments. This...
CRISPR-Cas System Advances as Molecular Weapon Against Bacteria
Recent developments spotlight CRISPR-Cas technologies evolving beyond genome editing into potent antibacterial agents. Leveraging the system's inherent viral defense mechanism, researchers are...
Breakthrough in Botulinum Neurotoxin Complex Structure Unveiled
Scientists at Stockholm University have resolved the complete 14-subunit structure of botulinum neurotoxin B complex using cryo-electron microscopy, revealing its unique assembly mechanism...
FDA Issues Complete Response Letters for Kidney Cancer and AMD Therapies
Telix Pharmaceuticals received a complete response letter (CRL) from FDA regarding its Zircaix renal cancer imaging agent, citing chemistry and manufacturing issues that will require additional...
AI Models Face Challenge in Genetic Perturbation Predictions
Researchers from EPFL critically evaluated the performance of advanced artificial intelligence models against simpler statistical approaches in predicting cellular responses to genetic...
Emerging Molecular Glue Degraders in Cancer Therapy
Recent insights have reclassified certain investigational anti-cancer agents, such as indisulam and tasisulam, as RBM39 molecular glue degraders targeting pre-mRNA splicing factors implicated in...
AI Harnessed to Discover Natural Antibiotics Amid Resistance Crisis
AMPLY, an AI-driven biotechnology company, is mining genomic 'dark matter' to identify antimicrobial compounds evolved by nature to combat drug-resistant infections. Utilizing machine learning...
Novo Nordisk’s $550M Pact Propels RNA Drug Innovation for Metabolic Diseases
Novo Nordisk has entered a multi-year collaboration worth up to $550 million with RNA therapeutics startup Replicate Bioscience. The agreement centers on developing next-generation obesity and...
Natera's Signatera ctDNA Assay Included in Major Bladder Cancer Trial
Natera's circulating tumor DNA test, Signatera, has been incorporated as a pre-specified secondary endpoint in the Phase III ARCHER trial assessing radiation therapy in muscle-invasive bladder...
Disruptions at CDC Amid Leadership Departure and Scientific Departures
The sudden ouster of CDC Director Susan Monarez shortly after her appointment sparked internal upheaval within the agency amid alleged conflicts with political directives, particularly regarding...
AbbVie Acquires Gilgamesh's Psychedelic Antidepressant in $1.2 Billion Deal
AbbVie announced acquisition plans for Gilgamesh Pharmaceuticals' investigational psychedelic drug Bretisilocin, designed for major depressive disorder (MDD), with a potential total value of up to...
Tempus Acquires Paige, Expanding AI in Digital Pathology
Tempus AI completed an $81.3 million stock-based acquisition of Paige, a digital pathology innovator known for developing the first FDA-cleared AI application in pathology diagnostics. The deal...
Breakthroughs in Protein Binder Design with BindCraft AI Pipeline
Researchers at EPFL have developed BindCraft, an AI-powered pipeline capable of ‘one-shot’ design of high-affinity functional protein binders across diverse therapeutic targets, including...
Prothena’s Alzheimer's Antibody Faces Safety Concerns From Brain Swelling
Prothena disclosed Phase 1 data for its amyloid-targeting antibody PRX012, revealing higher incidences of amyloid-related imaging abnormalities with edema (ARIA-E) relative to approved Alzheimer’s...
FDA Narrows COVID-19 Vaccine Approvals Ahead of Fall Season
The FDA approved updated COVID-19 booster shots from Pfizer, Moderna, and Novavax targeting a currently circulating coronavirus strain but limited authorization to high-risk groups, including...